Details of the Drug Pharmacogenomic Perturbation Atlas

General Information of Drug (ID: DMX2FZS)

Drug Name
Epothilone A Drug Info
Synonyms
Epothilone A; (-)-Epothilone A; Epo A; epothile; Epothilone-A; UNII-51E07YBX96; Epoa; 51E07YBX96; EP; Epothilones; Epothilon A; (1S,3S,7S,10R,11S,12S,16R)-7,11-dihydroxy-8,8,10,12-tetramethyl-3-((E)-1-(2-methylthiazol-4-yl)prop-1-en-2-yl)-4,17-dioxabicyclo[14.1.0]heptadecane-5,9-dione; 4,17-Dioxabicyclo[14.1.0]heptadecane-5,9-dione,7,11-dihydroxy-8,8,10,12-tetramethyl-3-[(1E)-1-methyl-2-(2-methyl-4-thiazolyl)ethenyl]-,(1S,3S,7S,10R,11S,12S,16R)-
Cross-matching ID
PubChem CID
448799
ChEBI ID
CHEMBL31549
CAS Number
CAS 152044-53-6
VARIDT Drug ID
DR01676

Consensus Signature of Drug Pharmacogenomic Perturbation (DPP)
Term Name NES FDR q-val Tag % Leading Edge Genes
Legionellosis 2.14 0.00e+0 51/57 (89.47%) CXCL3;CXCL2;CXCL1;...
Proteasome 2.11 0.00e+0 44/46 (95.65%) PSMD1;PSME4;PSMD3;...
Ribosome biogenesis in eukaryotes 2.10 0.00e+0 52/108 (48.15%) NVL;GNL2;NXF3;...
Spliceosome 2.10 0.00e+0 101/150 (67.33%) FUS;PRPF19;LSM7;...
Viral protein interaction with cytokine and cytokine re... 2.05 0.00e+0 84/100 (84%) CXCL3;CXCL2;CXCL1;...
NF-kappa B signaling pathway 1.96 4.97e-3 90/104 (86.54%) CXCL3;CXCL2;CXCL1;...
Amoebiasis 1.87 9.94e-3 99/102 (97.06%) CXCL3;CXCL2;CXCL1;...
IL-17 signaling pathway 1.85 8.70e-3 84/94 (89.36%) CXCL3;CXCL2;CXCL1;...
Rheumatoid arthritis 1.79 1.88e-2 78/93 (83.87%) CXCL3;CXCL2;CXCL1;...
Homologous recombination 1.77 2.09e-2 35/41 (85.37%) NBN;RPA2;BRCC3;...
Primary immunodeficiency 1.74 2.35e-2 33/38 (86.84%) CD8A;LCK;TAP2;...
Epithelial cell signaling in Helicobacter pylori infect... 1.74 2.15e-2 62/70 (88.57%) CXCL3;CXCL2;CXCL1;...
TNF signaling pathway 1.69 3.98e-2 103/112 (91.96%) CXCL3;CXCL2;CXCL1;...
Fatty acid degradation -1.79 3.52e-2 40/43 (93.02%) ACAT2;ACAT1;ACSBG1;...
Valine, leucine and isoleucine degradation -1.79 4.02e-2 42/48 (87.5%) ACAT2;AOX1;ACAT1;...
Metabolism of xenobiotics by cytochrome P450 -1.81 4.52e-2 49/77 (63.64%) GSTT2;GSTM1;ADH7;...
Synthesis and degradation of ketone bodies -1.90 2.01e-2 9/10 (90%) ACAT2;ACAT1;OXCT1;...
×

Pharmacogenomic Perturbation Across Diseases and Tissues

Breast
Breast adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
MCF7 CVCL_0031 Homo sapiens 10uM 6H, 24H
Fibrocystic breast disease
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
MCF-10A (Parent) CVCL_0598 Homo sapiens 1.11uM - 10uM 3H, 6H, 12H, 24H
Colon
Colorectal adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HT-29 CVCL_0320 Homo sapiens 10uM 6H
Hematopoietic system
Normal
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
ASC CVCL_U602 Homo sapiens 10uM 24H
Kidney
Normal (Immortalized)
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HA1E CVCL_0284 Homo sapiens 10uM 6H
Liver
Hepatoblastoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
Hep G2 CVCL_0027 Homo sapiens 10uM 6H
Lung
Lung adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
A549 CVCL_0023 Homo sapiens 10uM 6H, 24H
Non-small cell lung carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HCC515 CVCL_5134 Homo sapiens 10uM 6H
Prostate
Prostate carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
PC-3 CVCL_0035 Homo sapiens 10uM 6H, 24H
VCaP CVCL_2235 Homo sapiens 10uM 6H, 24H
Skin
Melanoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
A-375 CVCL_0132 Homo sapiens 10uM 6H